Yamada K, Ushio Y, Hayakawa T, Arita N, Huang T Y, Nagatani M, Yamada N, Mogami H
Cancer Res. 1987 Apr 15;47(8):2123-8.
To assess the rationale of intraarterial (i.a.) 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea chemotherapy, distribution of 14C-labeled 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)- 3-nitrosourea in rat glioma was studied after i.a. or i.v. infusion. Immediately after infusion, the tumor located in the hemisphere of intracarotid infusion received 4.6-fold higher radioactivity than the tumor located contralaterally to intracarotid infusion and 2.8-fold higher radioactivity than i.v. infusion. The difference was kept up to 30 min after i.a. infusion. Autoradiographic observation indicated rather uniform distribution of the tracer in the central portion of i.a. infusion. However, in the periphery of i.a. infusion, distribution of the tracer was nonhomogenous. The results indicate that i.a. 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea chemotherapy is useful when the tumor has high blood flow and is located in the center of an infused area.
为评估动脉内注射1-(4-氨基-2-甲基-5-嘧啶基)甲基-3-(2-氯乙基)-3-亚硝基脲化疗的理论依据，在大鼠胶质瘤模型中，分别经动脉内或静脉内注射后，研究了14C标记的1-(4-氨基-2-甲基-5-嘧啶基)甲基-3-(2-氯乙基)-3-亚硝基脲在大鼠胶质瘤中的分布情况。注射后即刻，位于颈内动脉注射侧半球的肿瘤接受的放射性比位于颈内动脉注射对侧的肿瘤高4.6倍，比静脉注射高2.8倍。这种差异在动脉内注射后30分钟内一直存在。放射自显影观察表明，示踪剂在动脉内注射中心部分分布较为均匀。然而，在动脉内注射周边区域，示踪剂分布不均匀。结果表明，当肿瘤血流丰富且位于注入区域中心时，动脉内注射1-(4-氨基-2-甲基-5-嘧啶基)甲基-3-(2-氯乙基)-3-亚硝基脲化疗是有效的。
